Skip to search formSkip to main contentSkip to account menu

brostallicin

Known as: 4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide) 
A synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

Brostacillin HydrochloridePNU 166196

Broader (2)

GuanidinesPyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and…
2013
2013
Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin
Brostallicin is a DNA minor groove binder that shows enhanced antitumor activity in cells with high glutathione S-transferase… 
2009
2009
Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin
Brostallicin is a DNA minor groove binder in phase II clinical trials. Here, we show that brostallicin induces γ-H2AX nuclear… 
2007
2007
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma…
Review
2004
Review
2004
Brostallicin: a new concept in minor groove DNA binder development
Brostallicin is a bromoacryloyl derivative of distamycin A, which has shown very promising preclinical activity against a variety… 
2003
2003
Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells
Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high… 
2003
2003
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
PURPOSE Brostallicin (PNU-166196) is a alpha-bromoacrylic DNA minor groove binder, currently in clinical evaluation. This drug… 
2003
2003
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
PURPOSE Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity… 
Highly Cited
2002
Highly Cited
2002
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Brostallicin (PNU-166196) is a synthetic alpha-bromoacrylic, second-generation DNA minor groove binder structurally related to… 
Review
2001
Review
2001
Development of distamycin-related DNA binding anticancer drugs
The relatively low therapeutic index of the clinically used alkylating agents is probably related to the fact that these… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)